Key Highlights:
- Shares traded near 9.5p, leaving a Market Value of around £24m to £25m across 259 million shares.
- The stock collapsed from a 22p January high to a 5.2p low on 20 February when the scandal broke.
- An internal investigation found around £0.77m of accrued Royalty income booked in FY25 was supported by fabricated documentation.
- Half-year Revenue rose 37.4% to £2.17m, with gross Margin broadly steady at 55.6%.
- Cash fell from £3.1m at 31 December 2025 to just £1.5m by 31 May 2026, with investigation costs of roughly £0.7m.
A microbiome pioneer that once traded above 22p is now nursing a share price in single digits, a former chief executive accused of fabricating revenue, and a set of half-year accounts that had to be restated. For a company built on the science of healthy skin, the wounds have been almost entirely self-inflicted — and investors are still counting the cost.
What happened to the shares?
SkinBioTherapeutics (LSE:SBTX), the Newcastle-based life-science group listed on London’s AIM market, has drifted lower again, with the latest screener snapshot pointing to a fall of around 5%. Recent live pricing had the stock changing hands near 9.5p, down roughly 3.8% on the day, on modest Volume of fewer than 200,000 shares. The precise size of any single session’s move is hard to pin down on a thinly traded small-cap where the bid-offer spread alone is around a penny — more than 11% of the share price — so the exact 5.3% figure quoted by screeners should be treated as indicative rather than gospel. What is not in doubt is the direction of travel.
The wider chart tells a brutal story. Over the past twelve months the shares have shed roughly a third of their value; a £1,000 stake a year ago would be worth a little over £660 today. The 52-week high of 22p was struck in mid-January 2026, only for the stock to collapse to a low of 5.2p by 20 February, when the scandal that has come to define the company’s year broke into the open. The current mid-single-digit price leaves SkinBioTherapeutics with a Market Capitalisation of around £24m to £25m across its 259 million shares in issue. This is a Business trading at a fraction of its former valuation, and the recent softness looks less like a fresh shock than the continued bleeding of confidence from an already deep cut.
What is driving the story?
The dominant force weighing on the shares is the fallout from a corporate governance scandal that has consumed SkinBioTherapeutics since February 2026. The company has published its half-year results for the six months to 31 December 2025 alongside restated figures for the year to 30 June 2025 — the accounts that had to be rebuilt after an internal investigation concluded that reported revenue had been fabricated. The arrival of those numbers, confirming the scale of the damage in black and white, is the clearest company-specific catalyst behind the recent weakness. Publishing restated accounts crystallises bad news that the market had feared but not fully quantified, and it reminds holders just how far the rehabilitation still has to run.
At the centre of the affair is former chief executive Stuart Ashman, appointed in 2024 and suspended in February 2026 before resigning. The board has accused him of misrepresenting material information to directors, senior management, the company’s auditors and the professional firms acting for it. The investigation — which drew in forensic accountants from FRP Advisory — found that around £0.77m of accrued royalty income booked in FY25 was supported by fabricated documentation, and it flagged improperly timed Bonus and consultancy payments to directors across FY24 and FY25. The reputational and financial consequences have rippled through the boardroom, and each fresh disclosure has given nervous investors another reason to sell.
Latest company developments
The most consequential recent event is the completion of the board investigation and the publication of its findings in June 2026, followed by the restated and half-year accounts. Chairman Martin Hunt and non-executive director Dr Cathy Prescott both stepped down on 8 June 2026, and both voluntarily repaid bonuses identified by the review. Alyson Levett has taken over as interim chair, Rachel Parsonage was appointed interim chief executive in March to steady the ship, and Emily Bertram has joined as chief financial officer and board member. The company is actively recruiting new non-executive directors to rebuild a depleted board.
The investigation has not come cheap. Professional and forensic costs linked to the probe have run to roughly £0.7m — a material sum for a company of this size and a direct drain on already thin cash reserves. Management has signalled that it intends to issue fresh market guidance later in the year, having withdrawn from the forecasts that were built on discredited numbers. Beneath the governance drama, the operating business continues to function: the Dermatonics topical foot-care range, the AxisBiotix oral supplement line, the Zenakine neurocosmetic ingredient commercialised through partner Croda, and the recently acquired Bio-Tech Solutions contract-services arm all remain in play.
Financial position
The half-year numbers offer a more encouraging read than the headlines suggest. Revenue for the six months to 31 December 2025 rose 37.4% to £2.17m, up from £1.58m a year earlier, helped by a full six months of trading from the Bio-Tech Solutions services division, which turned a small operating profit of around £0.08m on £1.2m of revenue. The products segment generated £1.15m, with Dermatonics contributing £0.98m. Gross margin held broadly steady at 55.6%, and the operating loss narrowed marginally to £1.00m, with a net loss of £0.79m.
The restated FY25 picture is far less flattering. Stripping out the fabricated £0.77m of royalty revenue cut reported FY25 turnover from £4.64m to £3.87m, widened the operating loss from £1.12m to £2.13m, and turned a reported EBITDA loss of £0.41m into a £1.40m loss. Cash is the pressure point. The group held £3.1m at 31 December 2025 but only £1.5m by 31 May 2026 — a sharp drawdown that reflects continued operating losses plus the hefty investigation bill. For a loss-making company, a cash pile that has more than halved inside five months is the single most important number in the accounts, and it frames the central question hanging over the shares: how long can SkinBioTherapeutics fund itself before it needs to raise money?
The bull case
For contrarians, the appeal is that the worst may already be known and priced in. The fabricated revenue has been excised, the implicated executives have gone, and a fresh Leadership team is in place with a clean slate. The underlying commercial story retains genuine substance: revenue is growing at a double-digit clip, the Croda relationship gives the group Blue-Chip validation and royalty upside through Zenakine, and the Bio-Tech Solutions Acquisition is already profitable at the operating level. At around £24m of market value, a buyer is paying comparatively little for a portfolio of microbiome intellectual property, real products on shelves and a services arm that generates cash. If new management restores credibility and delivers on the promised guidance, the recovery potential from a heavily depressed base could be significant.
The bear case
The bear case is equally forceful. A company that has admitted its accounts were fabricated carries a governance discount that can take years to shed, and trust, once broken, is slow to rebuild. The cash position is the acute risk: with £1.5m at the end of May, continued losses and a £0.7m investigation bill already absorbed, the odds of a dilutive fundraising look meaningful, and any placing on a beaten-down share price would hurt existing holders. The stock is illiquid, the spread is punitive, guidance has been withdrawn, and the board is still being reconstructed. Until investors can trust the numbers and see a clear path to breakeven or funded growth, the shares may struggle to escape the discount that scandal has stamped on them.
What could move the shares next?
Several catalysts loom. The promised reissue of market guidance will be pivotal — a credible, achievable forecast could begin to restore confidence, while a cautious one could confirm fears. Any announcement on funding, whether a placing, Debt Facility or strategic partnership, will move the stock sharply given the cash squeeze. The appointment of a permanent chief executive and new non-executive directors would signal that stabilisation is complete. Beyond governance, commercial newsflow — royalty milestones from Croda, new contract wins at Bio-Tech Solutions, or evidence that AxisBiotix and Dermatonics are scaling — could shift the narrative back towards the underlying business. Regulatory or legal developments stemming from the former CEO’s conduct remain a wildcard.
Investor takeaway
SkinBioTherapeutics (LSE:SBTX) is a genuine turnaround situation, and turnarounds are not for the faint-hearted. The half-year figures show a business that is growing and, at the operating level in parts, functioning well; the restated accounts and the flight of cash show a company that has paid a heavy price for a governance failure and is not yet out of the woods. The recent share-price slide reflects the market digesting confirmed bad news rather than any new bombshell. Whether the current valuation represents value or a value trap depends almost entirely on execution from here: on funding, on credible guidance and on rebuilt trust. Prospective investors should weigh the tangible commercial Assets against the real risk of dilution and the long shadow of the scandal, and size any exposure with the stock’s illiquidity firmly in mind.






Please wait processing your request...